Background. Potassium iodide often is prescribed prior to thyroidectomy for Graves' disease, but the effect of potassium iodide on the ease and safety of thyroidectomy for Graves' is largely unknown. Methods. We conducted a prospective, cohort study of patients with Graves' disease undergoing thyroidectomy. For the first 8 months, no patients received potassium iodide; for the next 8 months, potassium iodide was added to the preoperative protocol for all patients. Outcomes included operative difficulty (based on the Thyroidectomy Difficulty Scale) and complications. Results. We included a total of 31 patients in the no potassium iodide group and 28 in the potassium iodide group. According to the Thyroidectomy Difficulty Scale, gland vascularity decreased in the potassium iodide group (mean score 2.6 vs 3.3, P = .04), but there were no differences in friability, fibrosis, or size of the thyroid or in overall difficulty of operation (P = not significant for all). Despite similar operative difficulty, patients prescribed potassium iodide were less likely to experience transient hypoparathyroidism (7% vs 26%, P = .018) and transient hoarseness (0% vs 16%, P = .009) compared with the no potassium iodide group. Conclusion. Potassium iodide administration decreases gland vascularity, but does not change the overall difficulty of thyroidectomy. Preoperative use of potassium iodide solution was, however, associated with less transient hypoparathyroidism and transient hoarseness, suggesting that potassium iodide improves the safety of thyroidectomy for Graves' disease.
Graves' disease is the most common cause of hyperthyroidism in adults, the treatment options of which include radioactive iodine ablation, antithyroidal medications, and thyroidectomy. 1, 2 Clinical factors often dictate the patients' ultimate treatment choice, but thyroidectomy is becoming more common. 3, 4 Total thyroidectomy is now the preferred operation for those desiring surgical treatment instead of subtotal thyroidectomy due to its improved efficacy without increased complications. [5] [6] [7] [8] [9] [10] Despite the increasing utilization of thyroidectomy and the refined approach with a greater focus on patient safety and operative outcomes, total thyroidectomy remains technically challenging in patients with hyperthyroidism. 11 Administration of potassium iodide solution (KI) is recommended prior to thyroidectomy for Graves' disease because KI is thought to make the operation easier and safer. 7, 10, 12 Historically, KI in combination with propranolol controlled hyperthyroidism effectively even in the absence of currently available antithyroidal medications. 13 Now that newer antithyroidal medications are available, KI is used rarely as a means to control hyperthyroidism. 14 Instead, KI now is administered preoperatively, because it is generally thought to decrease vascularity and make the operation easier. Recently, a randomized study demonstrated that KI causes a measurable decrease in gland vascularity after noticing a significant decrease in blood flow on Doppler ultrasonography from 138 mL/ min before treatment to 75 mL/min after treatment. 12 This trial as well as another trial reported 50 to 100 mL less operative blood loss for patients administered KI compared with controls, which presumably improves visibility and facilitates surgical extirpation. 12, 15 Despite these findings, recent studies call into question the necessity of KI in preparing patients for thyroidectomy based on the absence of an observed increase in complications when KI is not used. 16, 17 Yet neither of these latter studies compared outcomes with a group of Graves' patients prepared for operation with KI. 16, 17 Ultimately, the impact of KI on the ease and safety of total thyroidectomy for Graves' disease remains largely unknown. Therefore, we aimed to quantify the difficulty of total thyroidectomy for Graves' disease based on preoperative preparation with KI. Our secondary aim was to evaluate if KI affects the safety of thyroidectomy by comparing complications in this same population.
Methods
We performed a prospective cohort study of patients presenting for operative treatment of Graves' disease during the 16-month period from May 2015 through August 2016. We excluded patients <18 years old or with a history of prior partial thyroidectomy. In an effort to streamline care protocols, all surgeons agreed to similar preparation strategies for patients with Graves' disease. Per the clinical protocol, all patients were given 1,000 mg calcium carbonate 3 times daily for 10 days prior to operation and for 2 weeks postoperatively. 18 For the first 8 months, no patients were prescribed KI. During the more recent 8 months, KI was added to the preoperative preparation for all patients. Patients were instructed to place 1 drop (0.05 mL) of a 1 g/mL KI solution on their tongue 3 times daily for 10 days prior to operation. All data were gathered prospectively, and outcomes included operative difficulty and operative complications. This study was in compliance with the Health Insurance Portability and Accountability Act and approved by the University of Wisconsin Institutional Review Board.
Total thyroidectomy was planned in all patients through a transverse cervical incision. The operating surgeon graded the difficulty of each thyroidectomy with the Thyroidectomy Difficulty Scale. 19 With this scale, the operating surgeon grades gland vascularity, friability, mobility (fibrosis), and size on 5-point Likert scales, with 1 representing the easiest thyroidectomy and 5 representing the most difficult. These grades are assigned at the conclusion of the case, and the sum of these 4 values is the overall thyroidectomy difficulty score. 11, 19 Additionally, this scale has an excellent inter-rater reliability and correlates with operative times and complications. 19 Routine parathyroid hormone levels obtained in the recovery room defined transient hypoparathyroidism if <10 pg/mL. We also considered patients who required calcitriol or large amounts of calcium beyond what was prescribed to have transient hypoparathyroidism. If patients required calcitriol or ≥2 g of calcium daily to prevent symptoms of hypocalcemia 6 months after the thyroidectomy, we considered their hypoparathyroidism permanent. Transient hoarseness was defined as clinically relevant changes in voice at the 2-week postoperative appointment. Injuries to the recurrent laryngeal nerve were diagnosed based on the patient's clinical voice, and symptoms of swallowing often were coupled with intraoperative nerve monitoring and laryngoscopy when appropriate. If patients had a loss of signal on a nerve monitor and voice changes, they were classified as having a nerve injury. Not all patients with postoperative voice changes underwent laryngoscopy. Laryngoscopy was obtained selectively based on symptom severity and time to resolution. Any persistent hoarseness after 6 months was considered permanent.
We compared patients in the first 8 months to patients from the last 8 months with an intention to treat analysis. The intention to treat analysis compared the practice of prescribing KI with not prescribing KI and indicated how a change in practice affected patient outcomes. We also compared patients who took KI as prescribed to those who did not take KI with a per protocol analysis. Descriptive statistics were reported as mean with standard deviation or as frequency with percent. χ 2 tests compared nominal variables, and Mann-Whitney U tests compared ordinal and continuous variables. All analyses were performed using SPSS 23 (IBM, Chicago, IL).
Results
The final study cohort included 59 patients undergoing surgery for Graves' disease, with 31 (53%) in the group not given KI and 28 (48%) in the KI group (Fig 1) . Of those in the KI group, 25 (89%) took the medication as directed. Patients in the no KI group were slightly older than those in the KI group (mean age 47 years vs 38 years, P = .016), but other demographic characteristics were similar between the 2 groups (Table I) . Patients were equally likely to receive antithyroidal medication (84% in the no KI group vs 89% in the KI group; P = .54), and the degree of preoperative blockade seemed similar based on patient hemodynamics (mean pulse 75 in the no KI group vs 77 in the KI group, P = .41) and free thyroxine levels (mean 1.3 in the no KI group vs 1.1 in the KI group, P = .40).
Thyroid difficulty
Operating surgeons calculated the Thyroidectomy Difficulty Scale scores at the conclusion of the operation. Thyroid difficulty scores were available for 50 patients (25 in each group). Overall, the difficulty level of thyroidectomy was similar between groups (mean score 10.4 without KI vs 9.5 with KI, P = .26). Using a score of 10 on the total scale as a cut-off for a difficult thyroidectomy as described previously, 11 the proportion of difficult thyroidectomies in each group was not different (56% in the no KI group vs 44% in the KI group, P = .40). When breaking down the score into its component parts, the group not given KI demonstrated greater gland vascularity (mean score 3.3 vs 2.6, P = .04), but there were no differences in mean scores for thyroid friability, mobility, and fibrosis, or for size (Fig 2) .
Operative complications
Even though the difficulty of the thyroidectomy was similar, patients who did not receive preoperative KI were more likely to experience transient complications compared with patients in the KI group (Table II) . Transient hypoparathyroidism was 3 times more likely to occur after thyroidectomy in patients not given KI (26% vs 7%, P = .049). Transient hoarseness persisting at least 2 weeks postoperatively also was more common in the group not given KI compared with those in the KI group (16% vs 0%; P = .009). Of those who had intraoperative monitoring of the recurrent laryngeal nerve (n = 54), 5 of 26 in the no KI group had a signal loss compared with 1 of 28 in the KI group. Only one definite nerve injury was identified in the no KI group and confirmed with laryngoscopy; none were identified in the KI group (P = .25). No patients in either group experienced permanent hypoparathyroidism, permanent hoarseness, or a hematoma, and no patients required readmission. The patient with a nerve injury had complete resolution of vocal cord function that was also confirmed with laryngoscopy.
Per protocol analysis
In general, per protocol analysis comparing patients who did not take KI to those who took KI as prescribed did not impact the difficulty or safety outcomes of thyroidectomy in these patients (Table III) . Of the 3 patients in the group prescribed KI who did not take the KI as planned, one patient had transient hypoparathyroidism, and the difference in the rate of transient hypoparathyroidism increased between patients who did not take KI (27%) compared with those who took KI as prescribed (4%; P = .014), but this difference was already significant in the intention to treat analysis.
Discussion
Although the necessity of KI in the preparation of Graves' patients for thyroidectomy is debated, its impact on the ease and safety of thyroidectomy is not well documented. Prior studies are small or have suboptimal control groups. Therefore, we sought to compare the effects of KI on operative difficulty and operative complications exclusively in patients with Graves' disease at a high-volume center. We found that overall operative difficulty was not greater in patients without KI, but these patients experienced a greater rate of transient complications.
We used an intention to treat analysis to compare the practice of routinely prescribing KI with the practice of never prescribing KI. Although 3 patients did not take KI as planned, our approach provided a realistic picture of outcomes in a practice where KI is prescribed preoperatively for all patients with Graves' disease. To address the conservative bias inherent to intention to treat analyses, we also reported data from a per protocol analysis where we grouped the aforementioned 3 patients with the group who did not take KI. Overall, outcomes were similar with both analyses indicating that bias did not skew our results drastically. Thyroidectomy difficulty based on whether or not KI was planned. This intention to treat analysis graphically displays the mean scores assigned to thyroidectomies in the groups of patients based on whether or not KI was planned as a part of the preoperative preparation. The thyroidectomy difficulty scale has a high inter-rater correlation and correlates well with operative times and operative complications. 19 Our data show that overall difficulty scores were not different between patients prepared for total thyroidectomy with and without KI. Even though patients without KI had only a 1-point greater mean difficulty, that small increase took the mean beyond the threshold of what is considered a difficult thyroidectomy based on the point at which operative times tended to be above the surgeon's average time. 11 This small shift resulted in a 10% greater chance of a difficult thyroidectomy in patients without KI. While these differences were not statistically significant (P = .26), the number of patients in our series (n = 59) was relatively small, and it is possible that KI may be beneficial in facilitating an easier thyroidectomy. In a prior, small randomized trial, subjective difficulty of thyroidectomy was not significantly less with KI, although only one-third of the planned participants were accrued, and the trial may have been underpowered to detect a difference. 15 Despite not being able to identify any overall improvement in the ease of thyroidectomy with KI, thyroid vascularity was significantly less in patients given KI. This finding is in agreement with prior reports. Erbil et al 12 demonstrated a significant decrease in blood flow on Doppler ultrasonography, intraoperative blood loss, and microvessel density on pathology in patients treated with KI preoperatively. Similarly, Whalen et al 15 also showed that KI decreased intraoperative blood loss during thyroidectomy. The present study grading thyroid vascularity on a 5-point Likert scale was able to translate what has been measured quantitatively to what is appreciated subjectively at the time of operation.
Even in the conservatively biased intention to treat analysis, KI was associated with significantly less transient hoarseness and hypoparathyroidism and the only documented nerve injury occurred in a patient that did not receive KI. Conversely, Shinall et al 16 found that patients with Graves' disease not prepared with KI had similar rates of transient nerve palsies and less transient hypoparathyroidism than patients with toxic multinodular goiters after thyroidectomy. They concluded that preoperative KI was not necessary. In a separate study looking exclusively at patients with Graves' disease, Shinall et al 17 found that noncompliance with the recommendations of the American Thyroid Association for the preoperative preparation of patients with Graves' disease (which includes KI administration) was not associated with increased complications, but their study cohort only included 3 patients who received KI preparation. 17 Even though defined slightly differently in the studies by Shinall et al, their observed rates of transient hypoparathyroidism (27-31%) were comparable with the group of patients not prepared with KI (26%) in the present study and substantially greater than the rate in the group who did receive KI (7%). 16, 17 These data suggest that the lack of a perceived benefit from KI administration in those studies is likely related to the limitations of the control groups rather than KI truly having no impact.
Although one might argue that the increased frequency of transient complications would, on a larger scale, predict increased permanent complications, the present study did not record any permanent complications. Given the absence of permanent complications, even in the absence of KI administration, total thyroidectomy is a safe and effective treatment option for patients with Graves' disease.
The present study has limitations. Although a relatively large population of patients with Graves' disease is represented, the size of our cohort prevented subgroup and multivariate analyses and places our results at risk for type II errors. Additionally, wide swings in proportions may have occurred with 1 or 2 additional events. Another limitation is the fact that surgeons were not blinded to the patients' preoperative preparation. It is difficult to quantify bias that may have been incorporated into the thyroidectomy difficulty scale scores, although the general consensus in the group prior to this study was that KI administration probably did not matter and that its routine use was likely not necessary. In this regard, our findings are in contrast to what our surgeons expected based on their beliefs prior to the study, which actually strengthens the potential importance of our results. Lastly, this prospective study is not a randomized clinical trial. While a clinical trial could help decrease selection bias, patients in the present study either did or did not receive KI based on when they presented to clinic, not based on specific surgeon preferences or disease characteristics. Furthermore, other attempts at studying KI in a trial have been limited by the few participants enrolled which resulted in insufficient power to detect a difference in complications rates. 12, 15 In conclusion, preoperative KI administration decreased gland vascularity but did not affect the overall difficulty of thyroidectomy for patients with Graves' disease. Total thyroidectomy is safe as a treatment for Graves' disease given that permanent complications (hypoparathyroidism and hoarseness) were absent with or without KI. Preparation with KI is associated with a lesser rate of transient hoarseness and transient hypoparathyroidism, suggesting that including KI in preoperative protocols does confer a safety advantage.
Dr Christopher R. McHenry (Cleveland, OH): I had 2 questions for you and one short comment. Very briefly, can you tell us what your regimen is, your dosage regimen is for the SSKI, in terms of the dose of the SSKI and how many days you use the SSKI prior to surgery?
And then, secondly, you gave us your subjective assessment of vascularity. Do you have any information on your estimated blood loss from the 2 groups?
And then, finally, you know, this is a great study. I think that one observation is, the way to even improve this study would have been ideally to have the surgeons blinded as to whether or not they were using the SSKI. But congratulations on an interesting study.
Dr Reese W. Randle: Thanks so much for your questions and that comment.
To answer your first question, the SSKI, we use Lugol's solution, which I believe is a gram per milliliter, and we had patients take one drop on their tongue 3 times a day for the 10 days prior to surgery. We encouraged them to mix it with something else, like orange juice, because the taste is pretty terrible, except for that last day on the day of surgery.
And as far as measuring operative blood loss, I found that estimate to be pretty unreliable. That outcome has been described before in prospective studies looking at potassium iodide solution. And so we didn't repeat that with this study. Moreover, we wanted to see what was previously shown as an objective difference in blood loss is appreciated by a surgeon's subjective perspective on the issue.
And I agree that blinding the surgeon would have been ideal. It adds a layer of complexity, as I'm sure that you're aware, that makes it a little bit more difficult to do the study. But I agree. It's interesting because our initial bias was that it didn't matter, that SSKI did not matter. However, we felt obligated to include it in our protocols because of the guidelines. And despite our initial bias, we found what seems to be an objective difference favoring the use of SSKI.
Dr Sareh Parangi (Boston, MA): Thanks for this great study. I have a quick question. I do use SSKI in my practice, but I think I have a higher hypocalcemia rate. So I was curious to see what your protocol is for this and whether you made any changes in that protocol when you initiated SSKI? Or were, really, all patients treated exactly alike? And it would be nice to know what it is, because I'd like to do it in my patients.
Dr Reese W. Randle: Thank you. So, all patients, as far as calcium goes, were treated similarly during the entire 16 months. The protocol we use for calcium is that we give everybody a gram of calcium carbonate. We just use Tums, but calcium carbonate 3 times a day for 10 days prior to surgery, and then we will carry that out for two weeks postoperatively, unless their PACU PTH is less than 10 in which case we will add Calcitriol.
Dr Richard Hodin (Boston, MA): Thanks for a nice study. Can you comment on gland size? Do you have data on that? I know the size was part of the difficulty score, but I'm talking about, you know, you see the patient preoperative because at least in my practice, you know, I tend to make sure I give the SSKI to the huge goiters, because I worry more about those really big ones and figure it helps more in those, but I actually don't have data on it. So, I am just wondering.
Dr Reese W. Randle: So preoperatively we don't have a good measure of the size of the thyroid gland. In addition to the scale, which is the subjective measure with anchoring points at one, 3 and 5 of how big the gland was, and like we saw, there's no difference there. But the gland weight measured by the pathologist was not also significantly different between the 2 groups. But, again, that's after one group had received Lugol's and one didn't. So, we don't have a good measure of the preoperative size.
Dr Richard Hodin (Boston, MA): But the complication rate, for example, had no relationship to the gland size? Or I guess the numbers are small to really say that.
Dr Reese W. Randle: We didn't look at gland size in terms of complications. But with them being similar, I don't know. It is a small number so it's hard to know if the gland size in this case affected the complication rate.
Thank you. Dr David J. Winchester (Evanston, IL): Thank you. Very nice paper. I have 2 questions. One, were there any important changes in your faculty during this study that could account for your conclusions, changes in the complication rates?
And my second question is, what do you believe is more important, your score, which is developed in the University of Wisconsin, or the study? And does this change of your practice? Dr Reese W. Randle: Thank you for your questions. So, there were some faculty changes during the study period. You know, I have never really run our complications by the staff, but all of our staff are high volume endocrine surgeons and have very low complication rates. And I don't think that played a big role in any differences seen in the study.
The way our practice is now, my practice is certainly that I will routinely prescribe SSKI; however, because there were no permanent complications noted in either group, I think it's still reasonable to do it without SSKI. And so if the patient for any reason doesn't want to take it or shows up to surgery and says that they have been noncompliant, then I won't hesitate to, you know, continue as planned.
But certainly, now I favor routinely using SSKI. Dr Richard A. Prinz (Evanston, IL): Two quick questions. Two things. This was a linear study. You didn't give SSKI, and then you did. I mean, so was there a change in terms of allowing more junior surgeons (i.e., fellows) to do the cases as the year went on in the second half of the study?
And, secondly, is there a dose dependency to SSKI? I have always given 10 drops in juice because it's such an awful thing twice a day.
Thank you. Dr Reese W. Randle: Thank you for your questions. So to keep my answers brief, the study period spans 16 months, and there was some graduated autonomy. You know, there are so many cases done that probably the majority of them are done by residents at various levels. And so that graduated autonomy changes month to month and is not a linear progression during the study. And also the 8 months did not correlate with an academic year exactly.
And to answer the other question, I am unaware of dose response on changes with SSKI.
